{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:53:54Z","timestamp":1777553634588,"version":"3.51.4"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Thalassemic patients have ineffective erythropoiesis. In recent treatment protocols, there are little data on folic acid supplementation for patients with thalassemia because it is supposed that regular blood transfusions prevent bone marrow hyperfunctioning.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>Investigators aimed to assess serum folic acid and homocysteine (Hcy) in thalassemia major patients before and after folic acid supplement cessation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>This study was a before-after controlled clinical trial conducted in 17th Shahrivar Hospital, Rasht, North of Iran, during May to October 2016. The patients enrolled in this study had thalassemia major on regular blood transfusion and older than 2 years of age. They had at least a 6-month history of folic acid supplement consumption before enrollment in the study (1\u2009mg\/daily). Complete blood count, serum folic acid, and serum Hcy were measured before discontinuation of folic acid supplement. Then, patients did not receive folic acid for a month and after 1 month of folic acid cessation, the measurements were repeated. All data were entered in SPSS version 20.0 and analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among the 40 patients in this study, 25 (62.5%) were female. The mean age of the participants was 21.39\u00b111.17 years old. The mean of body mass index was 21.38\u00b13.32\u2009kg\/m<jats:sup>2<\/jats:sup>. Most of the participants had used folic acid supplement &gt;5 years (29, 72.5%). The serum Hcy level was significantly increased (5.24\u00b12.35 vs. 5.93\u00b12.56; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.008) and serum folic acid level was decreased significantly (14.74\u00b14.20 vs. 8.80\u00b14.16; <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001) from baseline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Cessation of folic acid supplementations in beta thalassemia major patients can lead to a significant decrease in serum folic acid and increase in Hcy levels. According to our findings and efficacy of folic acid in patients with beta thalassemia major, it is recommended to use the supplementation in all patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000001295","type":"journal-article","created":{"date-parts":[[2018,8,19]],"date-time":"2018-08-19T23:42:22Z","timestamp":1534722142000},"page":"504-507","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of Serum Folic Acid and Homocysteine in Thalassemia Major Patients Before and After Folic Acid Supplement Cessation"],"prefix":"10.1097","volume":"40","author":[{"given":"Adel","family":"Baghersalimi","sequence":"first","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Pediatric Growth Disorders Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajar","family":"Hemmati Kolachahi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Pediatric Growth Disorders Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahram","family":"Darbandi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Pediatric Growth Disorders Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Kamran Mavardiani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical School, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Alizadeh Alinodehi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical School, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Setila","family":"Dalili","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Pediatric Growth Disorders Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afagh","family":"Hassanzadeh Rad","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Pediatric Growth Disorders Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0031-3955(02)00088-3","article-title":"Thalassemia: current approach to an old disease","volume":"49","author":"Lo","year":"2002","journal-title":"Pediatr Clin North Am"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2141.2007.06654.x","article-title":"Modern treatment of thalassaemia intermedia","volume":"138","author":"Borgna\u2010Pignatti","year":"2007","journal-title":"Br J Haematol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1749-6632.2010.05578.x","article-title":"Nutritional deficiencies in patients with thalassemia","volume":"1202","author":"Fung","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1365-2141.2009.07793.x","article-title":"Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America","volume":"146","author":"Vogiatzi","year":"2009","journal-title":"Br J Haematol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/jmri.21666","article-title":"Spleen R2 and R2* in iron\u2010overloaded patients with sickle cell disease and thalassemia major","volume":"29","author":"Brewer","year":"2009","journal-title":"J Magn Reson Imaging"},{"key":"R6-20230918","first-page":"266","article-title":"The effect of folic acid supplementation in beta-thalassemia major: a randomized placebo-controlled clinical trial","volume":"9","author":"Mojtahedzadeh","year":"2006","journal-title":"Arch Iran Med"},{"key":"R8-20230918","first-page":"241","article-title":"Serum erythrocyte folate levels in thalassaemic patients in Thailand","volume":"22","author":"Vatanavicharn","year":"1979","journal-title":"Eur J Haematol"},{"key":"R9-20230918","first-page":"183","article-title":"Behavior of blood folate in children with thalassemia major under transfusion therapy and in thalassemia trait","volume":"6","author":"Castagna","year":"1983","journal-title":"Acta Vitaminol Enzymol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1161\/01.ATV.17.10.1947","article-title":"Homocyst (e) ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial","volume":"17","author":"Evans","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R11-20230918","first-page":"414","article-title":"Heart Outcomes Prevention Evaluation (HOPE) 2 investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease","volume":"3","author":"Lonn","year":"2006","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMoa055227","article-title":"Homocysteine lowering and cardiovascular events after acute myocardial infarction","volume":"354","author":"B\u00f8naa","year":"2006","journal-title":"N Engl J Med"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ki.1997.359","article-title":"Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure","volume":"52","author":"Guttormsen","year":"1997","journal-title":"Kidney Int"},{"key":"R14-20230918","first-page":"365","article-title":"Elevated homocysteine levels in patients with end-stage renal disease","volume":"72","author":"Nair","year":"2005","journal-title":"Mt Sinai J Med"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/ajkd.2002.34887","article-title":"Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy","volume":"40","author":"Suliman","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/01.ASN.0000013299.11876.F6","article-title":"Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease patients","volume":"13","author":"Skoupy","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1007\/PL00014300","article-title":"The metabolism of homocysteine: pathways and regulation","volume":"157","author":"Finkelstein","year":"1998","journal-title":"Eur J Pediatr"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0271-5317(96)00128-5","article-title":"Dietary methionine imbalance, endothelial cell dysfunction and atherosclerosis","volume":"16","author":"Toborek","year":"1996","journal-title":"Nutr Res"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassemia","volume":"5","author":"Galanello","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1600-0609.2009.01377.x","article-title":"Nathan and Oski\u2019s hematology of infancy and childhood","volume":"84","author":"Hasle","year":"2010","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"R22-20230918","first-page":"28","article-title":"Serum folate level determination in major beta thalassemia patients","volume":"18","author":"Shamsian","year":"2008","journal-title":"Iran J Pediatr"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3748\/wjg.15.2081","article-title":"Importance of nutrition in inflammatory bowel disease","volume":"15","author":"Lucendo","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/anu.12275","article-title":"Effects of dietary folic acid on growth, antioxidant capacity, non\u2010specific immune response and disease resistance of juvenile Chinese mitten crab Eriocheir sinensis (Milne\u2010Edwards, 1853)","volume":"22","author":"Wei","year":"2016","journal-title":"Aquacult Nutr"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2016.00538","article-title":"Role of homocysteine in the ischemic stroke and development of ischemic tolerance","volume":"10","author":"Lehotsk\u00fd","year":"2016","journal-title":"Front Neurosci"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.pharep.2015.08.019","article-title":"Intensive statin therapy, used alone or in combination with ezetimibe, improves homocysteine level and lipid peroxidation to a similar degree in patients with coronary artery diseases","volume":"68","author":"Pytel","year":"2016","journal-title":"Pharmacol Rep"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-2000-12953","article-title":"Homocysteine metabolism and effects of folic acid supplementation in patients affected with spina bifida","volume":"31","author":"Brouwer","year":"2000","journal-title":"Neuropediatrics"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/00365510701516343","article-title":"Plasma homocysteine levels in patients with \u03b2\u2010thalassaemia major","volume":"68","author":"Ozdem","year":"2008","journal-title":"Scand J Clin Lab Invest"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201810000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T05:06:29Z","timestamp":1695013589000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201810000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001295","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}